ALK and small cell lung carcinoma: Notably, a literature review of 39 TKI-treated SLC-transformed LACs (37 EGFRM+ cases, 2 ALK-positive cases) [198] and a retrospective European cohort of 48 SCLC-transformed EGFRM+ LACs [199] displayed time to transformation, RR to platinum-etoposide, and OS since LAC diagnosis or after transformation comparable to those in the study by Marcoux et al. [195,198,199], thereby validating the conclusions in terms of clinical behavior of these tumors.